Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 994 results for "novartis"

GSK, Novartis complete $20bn asset swap deals
Trade Arabia

GSK, Novartis complete $20bn asset swap deals

GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the ... Trade Arabia, 7 hours ago
GlaxoSmithKline completes transaction with Novartis Economic Times, 15 hours ago
GSK, Norvatis sign deals worth $20bn Finance 24, 19 hours ago

285 images for novartis

Irish Times, 1 day ago
MedIndia, 1 day ago
Med India, 2 days ago
BDlive, 7 hours ago
NDTV, 4 days ago
Pharma Letter, 23 hours ago
Oman Observer, 20 hours ago
Pharmafocus, 1 day ago
Pharmaceutical Business Review, 1 day ago
Pretoria News, 1 day ago
The Telegraph

Novartis deal done, GSK sells local opiates business

 Pharma In Focus1 hour ago GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge  FiercePharma22 hours ago Novartis shares up nearly 2% at close  Economic Times2 months ago Novartis clarifies on CCI approval for GSK Pharma Deal  India Infoline2 months ago
Pharmaceutical Business Review

EMA committee recommends approval of Novartis' Zykadia in patients with ALK+ NSCLC previously treated with crizotinib

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Novartis drug Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small ...
 PharmaBiz7 hours ago EMA committee issues positive opinion for Novartis' lung cancer drug Zykadia  Pharmaceutical Business Review1 day ago NOVARTIS : EMA committee issues positive opinion for Novartis' lung cancer drug Zykadia  4 Traders9 hours ago

Novartis Treatment for Vision Loss Meets Goals in Study

Reuters Health Information By Reuters Staff March02,2015 ZURICH (Reuters) - Swiss drugmaker Novartis said on Friday its treatment for a leading cause of age-related blindness had met its primary goals in a study and could potentially pave the ...
 General Medicine eJournal14 hours ago

Novartis AG (NVS) Trading Near $103.56 Resistance Level

After closing Friday at $102.40, Novartis AG ("NVS) presents an attractive opportunity to get a 2.15% return in just 228 days, which is an annualized return of 3.43% (for comparison purposes only).
 Individual.com18 hours ago

Shares of Novartis Under Pressure, Down 2.1%

One of today's notable stocks in decline is Novartis (NYSE:NVS), down 2.2% to $100.10. The S&P is currently trading 0.4% higher to 2,114 and the Dow Jones Industrial Average is trading 0.7% higher
 Individual.com19 hours ago

GSK-Novartis deal 'a model' for industry

The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd. SHARE THIS QUOTE Tweet this quote Printed from: Print a single copy of this article ...
 Austin American Statesman20 hours ago

Novartis CEO talks about digitized medicine

BASEL, Switzerland -- Sit down with the chief of the world's biggest pharmaceutical company, and pretty soon the conversation will turn to the coming together of technology and biology. Call it digitized medicine. There will be an app for that. ...
 Nikkei Asian Review22 hours ago
Pharma Letter

Novartis hit with 15-day suspension over omission of adverse events reporting

Swiss drug major Novartis has been ordered to suspend operations in Japan for 15 days as of March 5,… In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login , take ...
 Pharma Letter23 hours ago Novartis Japan Hit With 15-day Suspension for Failing to Report Drug Side Effects  MedIndia2 days ago

Radius Appoints Former Novartis AG Executive To Board Of Directors

(GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive ...
 BioSpace21 hours ago Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors  Financial Content1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis
Get updated on latest news & your favorite topics right in your inbox!
More     Less